Ajinomoto Bio-Pharma Services
https://ajibio-pharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Ajinomoto Bio-Pharma Services
Ajinomoto Builds Gene Therapy CDMO Capabilities Through $554m Forge Acquisition
With an ambitious growth plan for its CDMO operations, Ajinomoto is planning to complete the acquisition of Forge Biologics Holdings by December, adding the US-based firm’s capabilities in gene therapy services.
Regeneron Targets Vulnerable Populations In COVID-19 Pact With BARDA
The company is developing a next-generation antibody for prevention of COVID-19 that targets highly conserved regions of the SARS-CoV-2 virus and thus may be able to overcome resistance.
AbbVie’s Aquipta & GSK’s Jesduvroq Move Closer To EU Market
AbbVie’s migraine prophylactic and GSK’s treatment for anemia associated with chronic kidney disease were both recommended for pan-EU marketing approval by the European Medicines Agency this week.
EU Crunch Time For Previously Rejected Lagevrio & Other New Drugs
MSD/Ridgeback Biotherapeutics’ COVID-19 treatment Lagevrio is among the products that are up for an opinion this week from the European Medicines Agency on whether they should be recommended for use across the EU.
Company Information
- Industry
- Contract Research, Toxicology Testing-CRO
- Pharmaceuticals
- Research, Analytical Equipment & Supplies
- Contract Manufacturing Organization
- Other Names / Subsidiaries
-
- Althea Technologies, Inc.
- Ajinomoto Pharmaceuticals Co., Ltd.
- EA Pharma Co., Ltd.
- GeneDesign
- OmniChem
- Granules OmniChem Private Limited
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice